Skip to main content
Clinical Trials/NL-OMON48783
NL-OMON48783CompletedNot Applicable

PHARMACOKINETICS OF APREPITANT, DEXAMETHASONE AND THEIR INTERACTION IN CHILDREN WITH CHEMOTHERAPY INDUCED NAUSEA AND VOMITING: A PILOT STUDY - Pharmacokinetics of aprepitant and dexamethasone

Prinses Máxima Centrum voor Kinderoncologie0 sites99 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
99

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
2 to 99 (—)

Inclusion Criteria

  • 1. Planned to receive chemotherapy intravenously as regular treatment (standard of care);
  • 2. Receiving granisetron/ondansetron; dexamethasone and/or aprepitant as standard of care
  • 3. Age * 6maanden en *19 years;
  • 4. Informed consent form (ICF) signed prior to participation in the study;
  • 5. A present central line to sample blood for pharmacokinetics;
  • 6. No Down syndrome or other syndromes that may influence regular dosing or no other disease/circumstances that may influence the participation of the subject in a negative way;
  • 7. No use of strong CYP3A4 substrates or inhibitors within 7 days or CYP3A4 inducers within 30 days of treatment (appendix 2);
  • 8. No current pregnancy
  • 9. During fertile age, extra none-hormonal contraceptives during the days of emend until 2 months after

Exclusion Criteria

  • see above, all described in the inclusion criteria

Investigators

Sponsor
Prinses Máxima Centrum voor Kinderoncologie

Similar Trials